Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative bridging antithrombotic strategy after recent drug-eluting stent implantation in non-cardiac surgery
ChiCTR1900022351Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirofiban and enoxaparin in coronary arteriosclerosis (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Blood routine, Bleeding and coagulation function and 7 more. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
tirofibanenoxaparin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900022351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022351.